A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)
A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)
This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits.
Inclusion Criteria:
Have a body mass index (BMI) ≥27.0 kilogram/square meter (kg/m²).
Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.
Have a diagnosis of Type 2 Diabetes (T2D), with HbA1c ≥7% (≥53 mmol/mol) to ≤10% (86 mmol/mol) and are on stable treatment for T2D for at least 90 days prior to screening, consisting of:
Exclusion Criteria:
Troy, Michigan 48098, United States
C.a.b.a., Ciudad Aut C1205AAO, Argentina
CABA, Ciudad Autónoma de Buenos Aire 1204, Argentina
Rosario, Santa Fe Province 2000, Argentina
SAN M. de Tucuman, Tucumán Province T4000AXL, Argentina
Luoyang Shi, Henan 471003, China
Dalian, Liaoning 116033, China
Pardubice V, Pardubice 530 02, Czechia
Pohlheim, Hesse 35415, Germany
Hohenmölsen, Saxony-Anhalt 06679, Germany
Lübeck, Schleswig-Holstein 23562, Germany
Mumbai, Maharashtra 400008, India
Seoul, Seoul-teukbyeolsi [Seoul] 06591, South Korea